Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 1 to 20 of 136

1.

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.

Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S.

Int J Gen Med. 2014 Jan 29;7:89-101. doi: 10.2147/IJGM.S51800. eCollection 2014.

PMID:
24501543
[PubMed]
Free PMC Article
2.

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA.

Onco Targets Ther. 2013 Dec 17;7:13-21. doi: 10.2147/OTT.S53348. eCollection 2013.

PMID:
24368888
[PubMed]
Free PMC Article
3.
4.

Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.

Collier P, Patel K, Waeltz P, Rupar M, Luthra R, Liu PC, Hollis G, Huber R, Verstovsek S, Burn TC.

Genet Test Mol Biomarkers. 2013 May;17(5):429-37. doi: 10.1089/gtmb.2012.0366. Epub 2013 Mar 28.

PMID:
23537216
[PubMed - indexed for MEDLINE]
5.

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.

Vaddi K, Sarlis NJ, Gupta V.

Expert Opin Pharmacother. 2012 Nov;13(16):2397-407. doi: 10.1517/14656566.2012.732998. Epub 2012 Oct 10. Review.

PMID:
23051187
[PubMed - indexed for MEDLINE]
6.

JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy.

Vaddi K, Luchi M.

Expert Opin Investig Drugs. 2012 Jul;21(7):961-73. doi: 10.1517/13543784.2012.690029. Epub 2012 May 22. Review.

PMID:
22612502
[PubMed - indexed for MEDLINE]
7.

The interplay between inhibition of JAK2 and HSP90.

Fridman JS, Sarlis NJ.

JAKSTAT. 2012 Apr 1;1(2):77-9. doi: 10.4161/jkst.20293.

PMID:
24058754
[PubMed]
Free PMC Article
8.

Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.

Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, Levy R, Williams W, Gottlieb A.

J Am Acad Dermatol. 2012 Oct;67(4):658-64. doi: 10.1016/j.jaad.2011.12.018. Epub 2012 Jan 24.

PMID:
22281165
[PubMed - indexed for MEDLINE]
9.

INCB38579, a novel and potent histamine H₄ receptor small molecule antagonist with anti-inflammatory pain and anti-pruritic functions.

Shin N, Covington M, Bian D, Zhuo J, Bowman K, Li Y, Soloviev M, Qian DQ, Feldman P, Leffet L, He X, He Wang K, Krug K, Bell D, Czerniak P, Hu Z, Zhao H, Zhang J, Yeleswaram S, Yao W, Newton R, Scherle P.

Eur J Pharmacol. 2012 Jan 30;675(1-3):47-56. doi: 10.1016/j.ejphar.2011.11.027. Epub 2011 Nov 27.

PMID:
22155710
[PubMed - indexed for MEDLINE]
10.

Small molecule immunomodulatory drugs: challenges and approaches for balancing efficacy with toxicity.

Haley PJ.

Toxicol Pathol. 2012;40(2):261-6. doi: 10.1177/0192623311427569. Epub 2011 Nov 14. Review.

PMID:
22083586
[PubMed - indexed for MEDLINE]
Free Article
11.

A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.

Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, Fridman JS, Behshad E, Wynn R, Li Y, Boer J, Diamond S, He C, Xu M, Zhuo J, Yao W, Newton RC, Scherle PA.

Clin Cancer Res. 2011 Nov 15;17(22):7127-38. doi: 10.1158/1078-0432.CCR-11-1157. Epub 2011 Sep 14.

PMID:
21918175
[PubMed - indexed for MEDLINE]
Free Article
12.

Development of c-MET pathway inhibitors.

Liu X, Newton RC, Scherle PA.

Expert Opin Investig Drugs. 2011 Sep;20(9):1225-41. doi: 10.1517/13543784.2011.600687. Epub 2011 Jul 11. Review.

PMID:
21740293
[PubMed - indexed for MEDLINE]
13.

Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.

Fridman JS, Scherle PA, Collins R, Burn T, Neilan CL, Hertel D, Contel N, Haley P, Thomas B, Shi J, Collier P, Rodgers JD, Shepard S, Metcalf B, Hollis G, Newton RC, Yeleswaram S, Friedman SM, Vaddi K.

J Invest Dermatol. 2011 Sep;131(9):1838-44. doi: 10.1038/jid.2011.140. Epub 2011 Jun 16.

PMID:
21677670
[PubMed - indexed for MEDLINE]
Free Article
14.

The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.

Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y, Landman RR, McKeever EG Jr, Punwani NG, Williams WV, Yeleswaram S.

J Clin Pharmacol. 2012 Jun;52(6):809-18. doi: 10.1177/0091270011405663. Epub 2011 May 20.

PMID:
21602517
[PubMed - indexed for MEDLINE]
15.

Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.

Shin N, Solomon K, Zhou N, Wang KH, Garlapati V, Thomas B, Li Y, Covington M, Baribaud F, Erickson-Viitanen S, Czerniak P, Contel N, Liu P, Burn T, Hollis G, Yeleswaram S, Vaddi K, Xue CB, Metcalf B, Friedman S, Scherle P, Newton R.

J Pharmacol Exp Ther. 2011 Jul;338(1):228-39. doi: 10.1124/jpet.111.179531. Epub 2011 Apr 1.

PMID:
21459966
[PubMed - indexed for MEDLINE]
Free Article
16.

Simultaneous determination of fluoxetine and its major active metabolite norfluoxetine in human plasma by LC-MS/MS using supported liquid extraction.

Li Y, Emm T, Yeleswaram S.

Biomed Chromatogr. 2011 Feb 10. doi: 10.1002/bmc.1597. [Epub ahead of print]

PMID:
21308704
[PubMed - as supplied by publisher]
17.

Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist.

Zheng C, Cao G, Xia M, Feng H, Glenn J, Anand R, Zhang K, Huang T, Wang A, Kong L, Li M, Galya L, Hughes RO, Devraj R, Morton PA, Rogier DJ, Covington M, Baribaud F, Shin N, Scherle P, Diamond S, Yeleswaram S, Vaddi K, Newton R, Hollis G, Friedman S, Metcalf B, Xue CB.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1442-6. doi: 10.1016/j.bmcl.2011.01.015. Epub 2011 Jan 11.

PMID:
21295478
[PubMed - indexed for MEDLINE]
18.

The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers.

Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y, Scherle PA, Punwani NG, Williams WV, Yeleswaram S.

J Clin Pharmacol. 2011 Dec;51(12):1644-54. doi: 10.1177/0091270010389469. Epub 2011 Jan 21.

PMID:
21257798
[PubMed - indexed for MEDLINE]
19.

11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus.

Hollis G, Huber R.

Diabetes Obes Metab. 2011 Jan;13(1):1-6. doi: 10.1111/j.1463-1326.2010.01305.x. Review.

PMID:
21114597
[PubMed - indexed for MEDLINE]
20.

Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.

Xue CB, Wang A, Meloni D, Zhang K, Kong L, Feng H, Glenn J, Huang T, Zhang Y, Cao G, Anand R, Zheng C, Xia M, Han Q, Robinson DJ, Storace L, Shao L, Li M, Brodmerkel CM, Covington M, Scherle P, Diamond S, Yeleswaram S, Vaddi K, Newton R, Hollis G, Friedman S, Metcalf B.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7473-8. doi: 10.1016/j.bmcl.2010.10.020. Epub 2010 Oct 13.

PMID:
21036044
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk